

11 000/μl, and diarrhoea lasting more than 7 days were significantly more common with *C. coli* infection. Other indices were not significantly associated with the species (or biotype) (table).

We cannot explain the apparent disagreement between our findings and the Yugoslavian study. We serotyped all strains with sera obtained by immunising rabbits with 52 campylobacter reference strains kindly provided by Dr Lior² and found that the distribution of serogroups among the index children and the others was similar. In other words, there was not a virulent serogroup of *C. coli* which accounted for severity of *C. coli* enteritis in our study group. *C. coli* was isolated in 15% of cases from Tuscany but in 35% in Popović-Uroić's series, and almost all our children were under 3 years of age while in the Yugoslavian study 46% of patients were over 5. Differences in the environmental circulation of the two *Campylobacter* spp. in the two countries, together with differences in age, may explain the disparity.

Infectious Diseases Clinic,
University of Siena,
53100 Siena, Italy

NATALE FIGURA
PAOLO GUGLIELMETTI

1. Lior H. New, extended biotyping schema for *Campylobacter jejuni*, *Campylobacter coli*, and *Campylobacter lariidis*. *J Clin Microbiol* 1984; 20: 636-40.
2. Lior H, Woodward DL, Edgar JA, Lianchi L J, Gill P. Serotyping of *Campylobacter jejuni* by slide agglutination based on heat-labile antigenic factors. *J Clin Microbiol* 1982; 15: 761-68.

SUBCUTANEOUS APOMORPHINE IN PARKINSON'S DISEASE

SIR,—Dr Stibe and colleagues (Feb 20, p 403) report on the benefit of continuous subcutaneous infusions of apomorphine hydrochloride in parkinsonian patients with response oscillations to oral levodopa. Stibe et al have also successfully used 'Penjects' in some cases.

We have treated four men and three women aged 44-68 (mean 57) years with intermittent subcutaneous injections of apomorphine for up to 6 months, using a penject system (Disetronic AG, Burgdorf, Switzerland). The pen contains 3.5 ml ampoules of apomorphine hydrochloride solution (10 mg/ml), and doses can be pre-set in multiples of 0.05 ml from 0.05 to 0.75 ml. The patients had had Parkinson's disease for 11 years on average (range 2½ to 15 years) and the daily levodopa doses ranged from 800 to 2500 mg (mean 1430 mg). All patients had three, four, or five off periods daily that were refractory to conventional treatment, including sustained-release levodopa. In five patients off periods were accompanied by prominent dystonia (painful feet in three, jaw spasms in one, and laryngeal stridor in one).

As Stibe et al found, subcutaneous apomorphine reversed off periods in all our patients 5-15 min after an injection, and the effect usually lasted 1.5-2.5 h. The doses required to produce an "on" effect were larger than those reported by Stibe et al and ranged from 2.5 to 7 mg (mean 4.7 mg). The average time "off" per day was reduced from 4.9 to 1.8 h but there was no significant reduction in the daily dose of levodopa. 30-60 mg oral domperidone daily prevented nausea from the apomorphine injections, and there were no laboratory abnormalities except slight eosinophilia in some. So far no psychotic side-effects have been observed.

Our patients found that they could quickly interrupt off phases and painful off-period dystonia, thus greatly improving the scope of social activities open to them; this social improvement may not always be reflected fully in the number of hours "on". For example, a 43-year-old woman with a 5-year history of Parkinson's disease had responded well to levodopa for 3 years when wearing-off reactions and very painful off-period foot dystonia appeared. Disabling foot cramps lasted up to 3 h and were especially severe in the early morning and late afternoon or evening. After some devastating experiences with dystonic spasms during visits to the theatre this woman had stopped going out in the evening. Her off-period dystonia proved very responsive to 2.5 mg apomorphine subcutaneously—and, with a penject in her handbag, she now feels free to go to concerts and the theatre and out for dinner.

In our experience subcutaneous apomorphine has been as practical and reliable a means of interrupting off-period dystonia as

intravenous levodopa.¹ In contrast to earlier reports^{2,3} neither we nor Stibe et al found differences in the effects of apomorphine on tremor and on akinesia/rigidity. The intermittent subcutaneous administration of apomorphine seems more convenient and simpler than the use of minipumps, and we agree with Stibe et al that this approach may be sufficient for many patients with oscillating Parkinson's disease including, in our opinion, some who are now on pumps.

WERNER POEWE
BIRGIT KLIEDORFER
FRANZ GERSTENBRAND

University Neurology Clinic,
A-6020 Innsbruck, Austria

Neurology Clinic,
Klinikum Grosshadern,
Munich, West Germany

WOLFGANG ÜRTEL

1. Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. *Ann Neurol* 1986; 23: 73-78.
2. Catzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I. Similarities between neurological effects of L-dopa and of apomorphine. *N Engl J Med* 1970; 282: 31-33.
3. Strain F, Mutschler E, Benkert O. Tremor inhibition in Parkinson syndrome after apomorphine administration under L-dopa and decarboxylase-inhibitor basic therapy. *Pharmakopsychiatri* 1972; 5: 198-205.

GROWTH IN CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKAEMIA

SIR,—We agree with the conclusions of Dr Clayton and colleagues (Feb 27, p 460). Controversy has raged for years over the contribution of growth hormone deficiency to growth failure in children treated with prophylactic cranial irradiation for acute lymphoblastic leukaemia (ALL). Although we agree with Kirk et al¹ that biochemical growth hormone deficiency is prevalent among patients receiving 2400 cGy of irradiation, the suggestion that growth hormone treatment is appropriate in most cases is contrary to our experience. We have reviewed 181 patients with ALL who were alive six years or more from diagnosis and who were diagnosed between 1970 and 1979.² We compared two groups: group I (n = 137) was those in first remission who had received a single course of cranial or craniospinal radiation (2400 cGy) and group II (n = 44) was those who had relapsed and required further radiation treatment (cranial, craniospinal, testicular, or total body irradiation). We did not compare growth by the height standard deviation score but, because endocrine data were included in a general survey of morbidity within the two groups, we found that 20% of group I had clinically significant endocrine morbidity. This included a high proportion of patients with early puberty leaving only 1 out of 137 who required replacement therapy for isolated growth hormone deficiency. Some degree of growth retardation was, however, common and we agree with Clayton and colleagues' suggestion that those children below the tenth centile whose growth is persistently poor, especially where growth hormone deficiency is demonstrated, would benefit from a trial of growth hormone. In contrast was the high frequency of endocrine morbidity (68%) in group II, where replacement therapy is normally required.

We have also done growth hormone studies in response to insulin-induced hypoglycaemia in 9 of 26 patients with early puberty who had received 1800-2400 cGy of prophylactic cranial irradiation. Of these, 8 had an inadequate growth spurt and 7 had a blunted or frankly subnormal response to hypoglycaemia (unpublished). In this situation, growth retardation and growth hormone insufficiency assume great importance when final height is compromised by an early inadequate growth spurt. Our practice has therefore been to treat with a gonadotropin-releasing-hormone analogue and growth hormone.

Department of Haematology and Oncology,
Hospitals for Sick Children,
London WC1N 3JJ

ALISON D. LEIPER
KATE WHEELER
JUDITH M. CHESSELLS

1. Kirk JA, Raghupathy P, Stevens MM, et al. Growth failure and growth-hormone deficiency after treatment for acute lymphoblastic leukaemia. *Lancet* 1987; i: 190-93.
2. Wheeler K, Leiper AD, Jannoun L, Chessells JM. Medical cost of curing childhood acute lymphoblastic leukaemia. *Br Med J* 1988; 296: 162-66.

THE LANCET

No 8591

LONDON SATURDAY 23 APRIL 1988

VOL I FOR 1988

ORIGINAL ARTICLES

Clinical Efficacy of a New, Enhanced-potency, Inactivated Poliovirus Vaccine 897
S. E. Robertson, MD, H. P. Traverso, MD, J. A. Drucker, MD, E. Z. Rovira, MS,
Bernard Fabre-Teste, MD, Abdourhamane Sow, MD, Mansour N'Diaye, MD,
M. T. A. Sy, MD, Foude Diouf, MD

Calcitonin for Prevention of Postmenopausal Bone Loss 900

Prof I. MacIntyre, FRCP, J. C. Stevenson, MRCP, M. I. Whitehead, MRCCOG,
S. J. Wimalawansa, MRCP, L. M. Banks, DCR, Prof M. J. R. Healy, MA

Cellular Anti-GP120 Cytolytic Reactivities in HIV-1 Seropositive Individuals 902
K. J. Weinhold, PhD, H. K. Lyerly, MD, T. J. Matthews, PhD, D. S. Tyler, MD,
P. M. Ahearne, BSE, K. C. Stine, MD, A. J. Langlois, PhD, Prof D. T. Durack, MD,
D. P. Bolognesi, PhD

Overuse Syndrome: a Muscle Biopsy Study 905

Xenia Dennett, PhD, H. J. H. Fry, FRACS

Red-cell-volume Distribution Curves in Diagnosis of Glomerular and Non-Glomerular Haematuria 908

Masayoshi Shichiri, MD, Kazushige Hosoda, MD, Yasuhide Nishio, MD,
Mitsuo Ogura, MD, Matsuhiko Suehaga, MD, Hiroshi Saito, MD, Shigeo Tomura, MD,
Tatsuo Shiigai, MD

METHODS AND DEVICES

Isolated Duodenal Tamponade for Treatment of Bleeding Duodenal Ulcer 911

T. V. Taylor, FRCS

REVIEWS

Notices of Books 912

OCCASIONAL SURVEYS

Mechanisms for the Early Mortality Reduction Produced by Beta-blockade Started Early in Acute Myocardial Infarction: ISIS-1 921

ISIS-1 (First International Study of Infarct Survival) Collaborative Group

The Role of Bone-marrow Transplants after Nuclear Accidents 923

Prof R. P. Gale, MD,
Yair Reisner, PhD

THERAPEUTICS

Dosage and Safety of Long-term Suppressive Acyclovir Therapy for Recurrent Genital Herpes 926

A. Mindel, MRCP,
A. Faherty, RGN,
O. Carney, RGN,
G. Patou, MB,
M. Freris, BSC,
P. Williams, MSc

BEFORE OUR TIME

Anorexia Nervosa in 1888 928
Prof J. A. Silverman, MD

ROUND THE WORLD

Nicaragua 930

IN ENGLAND NOW

COMMENTARY FROM WESTMINSTER 930

Humble Pie for the Government 951

PREVENTIVE MEDICINE

Avoiding Heart Disease 952

INTERNATIONAL DIARY

NOTES AND NEWS

AIDS in the UK 953

Human Rights Abuse in Mental Hospitals 953

Flying Epithalamium 954

Drugs for Orphan Diseases 954

International Agency for Research on Cancer 954

Obstruction or Reflux in Gallstone-associated Acute Pancreatitis? 915

Rabies Vaccine Failures 917

Screening for Hypertension in Childhood 918

Hyperlipidaemia after Renal Transplantation 919

Autoantibody Activity in Lambert-Eaton Myasthenic Syndrome 920

LETTERS TO THE EDITOR

Treatment of Osteosarcoma 931

Mr C. A. Siller, MSc

Prof Robert Souhami, Dr Alan Craft

Randomised Trial of Memory Training in the Over-60s 932

Dr Isabelle Neyroud and others

ABO Alloimmunisation after Intravenous Immunoglobulin Infusion 932

Dr Michael Potter and others

Small-intestinal Transit Time in the Elderly 933

Dr N. Y. Haboubi and others

Radiation, Cancer Risk, and the New Dosimetry and ICRP Inaction 933

Dr R. H. Mole

Pesticide Toxicity or Hypoglycine A Poisoning (Ivory Coast, 1984)? 934

Dr Thierry Brun

Immunological Reactivity and Bioactivity of Tumour Necrosis Factor 934

Dr C. M. Petersen, Dr B. K. Møller

Water Standards for Fluoride 935

Dr A. K. C. Leung

Monoclonal Antibodies to HIV in a Non-infected, Immunised Volunteer 935

Dr C. Desgranges and others

HIV and Polyarthritis 936

Dr Paul Davis and others

Group-specific Component and AIDS: Erroneous Data 936

Dr L. J. Eales and others

Updated Kiel Classification 937

Dr M. A. Richards, Dr A. G. Stansfeld

Cure of *Pseudomonas aeruginosa* Infection in Neutropenic Patients by Continuous Infusion of Ceftazidime 937

Dr S. Daenen, Dr H. de Vries-Hospers

Problem with Aspirin as Antithrombotic Agent in Coronary Artery Disease 937

Prof J. D. Folts and others

Chronic Sinus Node Disease and Coronary Artery Disease 938

Dr T. O. Cheng

Thrombolytic Therapy for Myocardial Infarction 938

Dr A. J. McNeill, Dr A. A. J. Adgey

Prophylactic Low-dose Aspirin and Dipyridamole in Pregnancy 939

Prof H. C. S. Wallenburg, Dr N. Rotmans

Diabetic Retinopathy 939

Dr J. T. Beranek

Violence, Nursing and Inpatient Psychiatry 940

Dr Iqbal Singh;

Dr D. V. James and others;

Dr A. K. Shah, Dr J. Piachaud

Children, Violence, and Southern Africa 940

Dr A. R. Noorahmed, Dr Julie Cliff

Editorial Freedom in South Africa 941

Dr N. C. Lee

Distinction Awards

Dr A. E. A. Joseph;

Dr Roger Gabriel;

Dr P. M. Smith

Death of a Soldier 941

Dr A. M. W. Porter

Life under Pyllons

Dr R. A. F. Cox

Accuracy of Bibliographic Data Bases 942

Dr A. Pinatis

Clinical Characteristics of *Campylobacter jejuni* and *C. coli* enteritis 942

Dr Natale Figura, Dr Paolo Guglielmetti

Subcutaneous Apomorphine in Parkinson's Disease 943

Dr Werner Poewe and others

Growth in Children Treated for Acute Lymphoblastic Leukaemia 943

Dr A. D. Leiper and others

Maternal Hepatitis B Infection Affects Fetal IgE Synthesis 944

Dr R. Y. M. Tseng and others

Legionella: a Case for Culture 944

Dr S. F. Perry and others

Raynaud's Phenomenon and Cryoglobulinaemia Associated with the Use of Recombinant Human Alpha-interferon 944

Dr V. Roy, Dr A. C. Newland

Bone Marrow Transplantation from Programmed Donor: One Year on 945

Dr G. R. Burgio and others

Chloride-free Oral Rehydration 945

Dr J. B. Leiper, Dr R. J. Maughan

New Dual Form of Porphyria 945

Dr Manfred Doss

Renal Allograft Survival in Transfused and Non-transfused Patients 946

Dr Neil Blumberg, Dr Joanna Heal

Natural History of Localised Prostatic Cancer 946

Mr E. P. N. O'Donoghue, FRCS and others

Lipid Deposition in Central Venous Catheters: a Solution 947

Dr C. R. Pennington and others

Short-course Alpha-interferon Therapy in Severe Unresponsive Immune Thrombocytopenic Purpura 947

Dr S. J. Proctor and others

Infant Nutrition and Adult Health 947

Dr A. E. Dugdale

Retroviruses in Monocytes from Patients with Breast Cancer 949

Prof Michael Baum and others

Carbon Dioxide, Brain Damage, and Cardiac Surgery 949

Dr Michael Nevin, Mr J. R. Pepper, FRCS

Blue Dyes in Reconstructive Surgery 949

Mr B. M. Jones, FRCS,

Mr D. T. Gault, FRCS

Recombinant Human Granulocyte-macrophage Colony-stimulating Factor Produces Fever 950

Dr W. P. Peters and others

Yawning 950

Dr M. P. I. Weller

CORRECTION

Prenatal Exclusion of Hereditary Retinoblastoma 954

Offices: 46 Bedford Square, London WC1B 3SL. Telephone: 01-436 4981 Fax: 01-436 7550 Telex: 291785. ISSN 0140-6736. Founded 1823. Published weekly. Registered as a Newspaper at the Post Office. Annual Subscription £51.00 (U.K. & Eire). The whole of the literary matter in The Lancet is copyright. © The Lancet Ltd, 1988. Price £2.75